Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma
C. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.
Exploring Challenges With CAR T Cells and NK Cells in Multiple Myeloma
C. Ola Landgren, MD, PhD, discusses the use of chimeric antigen receptor T cells and CAR natural killer cells in the multiple myeloma setting.
The Treatment of Older Patients With Multiple Myeloma
C. Ola Landgren, MD, PhD, a senior investigator in the Multiple Myeloma Section of the National Cancer Institute, discusses the treatment of older patients (over age 70) with multiple myeloma.